Overall survival in patients with metastatic hormone-sensitive prostate cancer treated with enzalutamide or placebo plus androgen deprivation therapy who had prior local therapy: post hoc analysis of the phase 3 arches trial
Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: A systematic review and meta-analysis
High-dose radiotherapy or Androgen Deprivation Therapy (HEAT) as treatment intensification for localized prostate cancer: An individual patient–data network meta-analysis from the MARCAP consortium
A multivariable approach using magnetic resonance imaging to avoid a protocol-based prostate biopsy in men on active surveillance for prostate cancer— data from the international multicenter prospective PRIAS study
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial